Impact of testosterone therapy on bone turnover markers in obese males with type 2 diabetes and functional hypogonadism

Fifty-five obese males with type 2 diabetes mellitus and functional hypogonadism participated in a 2-year, double-blind, placebo-controlled study of testosterone undecanoate (TU). Bone turnover markers C-telopeptide of type I collagen (CTX) and procollagen I N-terminal propeptide (PINP) were assesse...

Full description

Saved in:
Bibliographic Details
Published in:The aging male 2022-12, Vol.25 (1), p.269-277
Main Author: Groti Antonič, Kristina
Format: Article
Language:English
Subjects:
Aging
Biomarkers
Bone Density
bone mineral density
Bone Remodeling
Collagen Type I
Diabetes
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - drug therapy
Endocrine therapy
fracture
Humans
hypogonadism
Hypogonadism - complications
Hypogonadism - drug therapy
Lumbar Vertebrae - diagnostic imaging
Male
Mens health
Obesity
Obesity - complications
Obesity - drug therapy
Older people
Osteoporosis
Testosterone
Type 2 diabetes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Fifty-five obese males with type 2 diabetes mellitus and functional hypogonadism participated in a 2-year, double-blind, placebo-controlled study of testosterone undecanoate (TU). Bone turnover markers C-telopeptide of type I collagen (CTX) and procollagen I N-terminal propeptide (PINP) were assessed at baseline, 12 and 24 months. Bone mineral density (BMD) changes were evaluated after 24 months using dual-energy X-ray absorptiometry. Group T (n = 28) received TU both years. Group P (n = 27) received placebo first year and TU second year. CTX decreased in group P from 1055 (676-1344) to 453 (365-665) pmol/L (p 
ISSN:1368-5538
1473-0790
DOI:10.1080/13685538.2022.2134338